Avenzo Therapeutics

We’re pleased to announce the initiation of the combination cohort evaluating our potential best-in-class CDK4 and CDK2 selective inhibitors in the ongoing Phase 1 portion of our ORION-1 Phase 1/2 study, exploring a dual CDK4 and CDK2 selective inhibition approach in patients with HR+/HER2- metastatic #breastcancer.   This milestone marks another step forward as we continue to advance our pipeline and develop next-generation therapies aimed at improving outcomes for patients. Learn more in our press release: https://bit.ly/4efvMWE

We’re excited to announce the acceptance of an abstract for poster presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.   We look forward to sharing updated safety and efficacy results from the Phase 1 portion of our ongoing Phase 1/2 clinical study of our potential best-in-class cyclin-dependent kinase 2 (CDK2) selective inhibitor. #breastcancer #solidtumors #ASCO26 https://bit.ly/4sRNa7o

Today we celebrate our #TeamAvenzo colleagues in San Diego and around the country - a passionate group united by our mission to develop the next generation of #oncology therapies for patients in need. Thank you for bringing purpose, expertise, and heart to everything you do! #EmployeeAppreciationDay

This month we welcomed two new members of #TeamAvenzo! Ling He joins as executive director, Bioanalytical, and Jim Xia joins as manager, Statistical Programming. We look forward to the contributions they will make as we continue to advance our pipeline of potential best-in-class #oncology therapies for patients with high unmet medical needs.

Today, at the San Antonio Breast Cancer Symposium (#SABCS25), hosted by UT Health San Antonio and the American Association for Cancer Research (AACR), we’re presenting initial clinical results from the Phase 1 portion of our ongoing Phase 1/2 clinical study of our potential best-in-class cyclin-dependent kinase 2 (CDK2) selective inhibitor. The data showed preliminary clinical activity, including objective responses in patients with HR+/HER2- breast cancer and cyclin E1 (CCNE1)-amplified ovarian cancer, and that it was generally well tolerated. We look forward to presenting these results and advancing the development of this CDK2 inhibitor for patients with #breastcancer. Learn more: https://bit.ly/4rSr4Ci

We are proud to share that the U.S. Food and Drug Administration granted Fast Track designation to our potential best-in-class Nectin4/TROP2 bispecific antibody-drug conjugate for the treatment of patients with locally advanced or metastatic #urothelialcancer previously treated with enfortumab vedotin.   This designation represents an important step toward delivering meaningful change for patients by advancing next-generation oncology therapies for individuals with high unmet need. Learn more: https://bit.ly/4p1ZCAu

We are pleased to announce the appointment of Scott Lipman, M.B.A., as our new Chief Financial Officer.   In his expanded role as CFO, Scott will lead our finance & accounting functions while continuing to serve as Chief Business Officer, overseeing our business development efforts, as we advance our clinical-stage #oncology programs and prepare for the company’s next stage of growth.   Read the full press release here: https://bit.ly/3LLt5jo

We’re proud to announce that the U.S. Food and Drug Administration has granted Fast Track designation to our potential best-in-class EGFR/HER3 bispecific antibody-drug conjugate for the treatment of EGFR-mutated TKI-pretreated non-small cell #lungcancer (NSCLC). This important milestone reaffirms our commitment to developing next-generation oncology therapies that help make a difference in the lives of patients. Learn more: https://bit.ly/3JTEZac #oncology #fasttrackdesignation

We’re excited to announce the acceptance of two abstracts for poster presentations at the upcoming 2025 San Antonio Breast Cancer Symposium in December, hosted by UT Health San Antonio and the American Association for Cancer Research. We look forward to sharing preliminary safety and efficacy results from the Phase 1 portion of our ongoing Phase 1/2 clinical study of our potential best-in-class cyclin-dependent kinase 2 (CDK2) selective inhibitor. We’ll also highlight the Phase 1/2 study design of our potential best-in-class cyclin-dependent kinase 4 (CDK4) selective inhibitor in patients with advanced #solidtumors. http://bit.ly/3Wxgpi7 #SABCS25

We’re excited to highlight our potential best-in-class EGFR/HER3 bispecific antibody-drug conjugate (BsADC) during a poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets & Cancer Therapeutics, hosted by the American Association for Cancer Research.    We look forward to sharing details from our Phase 1/2 study evaluating our BsADC in patients with locally advanced or metastatic #solidtumors, and to connecting with fellow industry leaders to advance targeted therapies in #oncology.  #Targets25